CacheTech Inc. Purchases 4,191 Shares of Pfizer Inc. (NYSE:PFE)

by · The Cerbat Gem

CacheTech Inc. increased its position in Pfizer Inc. (NYSE:PFE – Free Report) by 22.3% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 22,976 shares of the biopharmaceutical company’s stock after buying an additional 4,191 shares during the quarter. CacheTech Inc.’s holdings in Pfizer were worth $610,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of PFE. Retirement Wealth Solutions LLC purchased a new position in shares of Pfizer in the fourth quarter valued at about $26,000. Rialto Wealth Management LLC bought a new position in Pfizer in the 4th quarter worth approximately $26,000. Kohmann Bosshard Financial Services LLC purchased a new stake in Pfizer during the 4th quarter valued at approximately $28,000. Noble Wealth Management PBC purchased a new stake in Pfizer during the 4th quarter valued at approximately $31,000. Finally, Curio Wealth LLC bought a new stake in shares of Pfizer during the fourth quarter valued at approximately $32,000. Institutional investors own 68.36% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the stock. Citigroup restated a “neutral” rating on shares of Pfizer in a research report on Thursday, March 27th. UBS Group reduced their target price on Pfizer from $28.00 to $24.00 and set a “neutral” rating on the stock in a report on Tuesday, April 8th. Truist Financial dropped their price target on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research note on Wednesday, December 18th. Guggenheim restated a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. Finally, Hsbc Global Res raised Pfizer to a “strong-buy” rating in a report on Monday, March 10th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have given a buy rating and three have given a strong buy rating to the stock. According to MarketBeat, Pfizer presently has an average rating of “Moderate Buy” and an average target price of $31.07.

View Our Latest Research Report on PFE

Pfizer Trading Up 0.9 %

Shares of PFE opened at $22.10 on Tuesday. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $31.54. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The company’s fifty day simple moving average is $25.16 and its 200-day simple moving average is $26.33. The company has a market cap of $125.34 billion, a P/E ratio of 15.67, a P/E/G ratio of 0.64 and a beta of 0.67.

Pfizer (NYSE:PFE – Get Free Report) last announced its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business had revenue of $17.76 billion during the quarter, compared to analyst estimates of $17.26 billion. During the same quarter in the previous year, the business earned $0.10 earnings per share. The company’s revenue for the quarter was up 24.7% compared to the same quarter last year. As a group, analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Insider Buying and Selling at Pfizer

In related news, Director Ronald E. Blaylock bought 19,457 shares of the stock in a transaction dated Thursday, February 13th. The stock was purchased at an average cost of $25.65 per share, with a total value of $499,072.05. Following the completion of the purchase, the director now owns 27,707 shares of the company’s stock, valued at $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 0.06% of the stock is currently owned by corporate insiders.

About Pfizer

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Featured Articles

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Free Report).